• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Recombinant Human Erythropoietin
    4 Drugs classified under this drug class


    All the Drug Class Drugs

    Aranesp
    Amgen
    RX
    partial basket chart
    Aranesp

    Recombinant Human Erythropoietin. Darbepoetin Alfa 10, 20, 30, 40, 50, 60, 80, 100, 150, 300, 500 mcg.
    PREFILL. SYRINGES (for single use only, with/out automat. needle guard): 4 x 10 μg; 20 μg; 30 μg; 40 μg; 50 μg; 60 μg; 80 μg; 100 μg, 150 μg; 1 x 300 μg, 500 μg. For I.V. and S.C. admin. Similar efficacy in I.V. and S.C. admin.
    PREFILL. PEN (SureClick) (single use only): 1 x 20 μg, 40 μg, 60 μg, 80 μg, 100 μg,150 μg, 300 μg, 500 μg. S.C. admin only.
    Tmt. anem. assoc. with chron. ren. fail. in adults and pediatric subjects 1 yrs of age and over. Aranesp 150, 300, 500 -also tmt. anem. in adult cancer pts. with non-myeloid malignancies receiv. chemother.
    C/I:
    Hpersenes. Poorly control. hypertens.

    Binocrit
    Novartis
    RX
    partial basket chart
    Binocrit

    Recombinant Human Erythropoietin. Epoeitin Alpha 1,000 IU/0.5 ml, 2,000 IU/1 ml, 3,000 IU/0.3 ml, 4,000 IU/0.4 ml, 5,000 IU/0.5 ml, 6,000 IU/0.6 ml, 8,000 IU/0.8 ml, 10,000 IU/1 ml, 20,000 IU/0.5 ml, 30,000 IU/0.75 ml, 40,000 IU/1 ml.
    Prefilled syringes (ready to
    use):1,6×1000IU/0.5ml, 2000IU/1ml,
    3000IU/0.3ml, 4000IU/0.4ml,
    5000IU/0.5ml, 6000IU/0.6ml,
    8000IU/0.8ml, 10000IU/1ml,
    20000IU/0.5ml, 30000IU/0.75ml &
    40000IU/1ml.
    Tmt. and dosage has to be initiated
    and adjust. individ. for each pt. accord.
    to the med. condit.
    Tmt. of symptom. anaemia assoc.with
    chron.renal fail.(CRF) in adult and
    paediatric pts.:- Tmt. of anaemia assoc.
    with chron. ren. fail.in paed. and adult pts.
    on haemodialysis and adult pts. on
    periton. dialysis.- Tmt. of sev. anaemia of
    renal origin accomp. by clin. sympt. in
    adult pts. with ren. insuffic. not yet
    undergoing dialysis. Tmt. of anaemia and
    reduct. of transfus. requirem. in adult pts.
    receiv. chemother. for solid tumour.,
    malign. lymphoma or multiple myeloma,
    and at risk of transfus. as assessed by the
    patient’s gener. status (e.g. cardiovascular
    status, pre existing anaemia at the start of
    chemother.). Binocrit can be used to
    increase the yield of autologous blood from pts. in a predonation programme. Its
    use in this indicat. must be balanced
    against the reported risk of thromboemb.
    events. Tmt. should only be given to noniron
    defic. pts. with moder. anaem.
    (haemoglobin (Hb) 10 13 g/dl (6.2 8.1
    mmol/l)), if blood saving procedur. are not
    available or insuffic. when the scheduled
    major elect. surg. requires a large volume
    of blood (4 or more units of blood for
    females or 5 or more units for males). The
    drug can be used to reduce exposure to
    allogeneic blood transfus. in adult non
    iron defic. pts. prior to major elective
    orthopaedic surg., having a high perceived
    risk for transfus. complicat. Use should be
    restricted to pts. with moder. anaemia (e.g.
    Hb 10 13 g/dl) who do not have an
    autolog. predonation programme
    available and with an expect. blood loss of
    900 to 1800 ml.
    C/I: Hypersens., pts. who develop PRCA
    follow. tmt. with any erythropoietin
    should not receive this drug or any other
    erythropoietin.

    Eprex
    Janssen
    RX
    partial basket chart
    Eprex

    Recombinant Human Erythropoietin. Recombinant-human Erythropoietin 2,000 U/0.5ml, 3,000 U/0.3ml, 4,000 U/0.4ml, 5,000 U/0.5ml, 6,000 U/0.6ml, 8,000 U/0.8ml, 10,000 U/ml, 20,000 U/0.5ml, 30,000 U/0.75ml, 40,000 U/ml.
    PREFILL. SYRINGES: 2,000 U/0.5 ml, 3,000 U/0.3 ml, 4,000 U/0.4 ml, 5,000 U/0.5 ml, 6,000 U/0.6 ml, 8,000 U/0.8 ml. 10,000 U/ml, 20,000 U/0.5 ml, 30,000 U/0.75 ml, 40,000 U/ml. For I.V. or S.C. admin. See lit.
    Severe anem. assoc. with chron. renal fail; zidovudine treated HIV infect. pts; cancer pts. on chemother.; autolog. blood predonat.; perisurgery.
    C/I: Hypersens.
    Pts. who develop pure red cell aplas. (PRCA) follow. tmt. with any erythropoietin should not receive EPREX or any other erythropoietin.
    Uncontrol. hypertens.
    All contraindications assoc. with autologous blood predonation program. should be respect. in pts. being supplem. with epoetin alfa.
    The use of epoetin alfa in pts. scheduled for major elect. orthopaedic surg. and not participat. in an autologous blood predonation program. is contraindic. in pts. with severe coronary, peripher. arterial, carotid or cerebr. vasc. dis., includ. pts. with recent MI or cerebral vasc. accident.
    Surg. פts. who for any reason cannot receive adequate antithrombot. prophylax.

    Recormon
    Roche
    RX
    partial basket chart
    Recormon

    Recombinant Human Erythropoietin. Epoeitin Beta 4000, 5000, 6000, 10000, 30000 IU.
    PREFILLED SYR.: 6 x 4000 IU/ 0.3 ml,
    5000 IU/ 0.3 ml, 6000 IU/ 0.3 ml, 10,000
    IU/ 0.6 ml,4 x 30,000 IU/ 0.6 ml.
    Adjust accord. to indic. and pt’s
    medic. condit. See lit.
    Tmt. anem. with chron. ren. fail. (ren.
    anemia) in pts. on dialysis; tmt. sympt.
    ren.
    anem. in pts. not yet undergoing dialysis;
    tmt. anem. in adults with solid tumors
    receiv. chemother.; tmt. anem. adults
    with multiple myeloma, low grade Non-
    Hodgkin’s lymphoma, chron. lymphocyt.
    leukem. With relative erythropoietin
    defic. receiv. Antitumor ther.; incr. yield of autologous blood from pts. in predonation
    program. See lit.
    C/I: Hypersens., Poorly controlled HTN,
    In the indication “incr. the yield of
    autologous blood”: MI or stroke in the
    month preceding tmt., unstable
    angina pect., incr. risk of DVT such as
    history of venous thromboem. dis.

    CLOSE